Clearmind's CMND-100 Shows Positive Safety in Phase I/II AUD Trial Part A
CMND is trading near its 52-week low of $1.43 (13% above the low) on light trading volume (0.1× avg).
Summary
Clearmind Medicine reported positive safety and tolerability results for its CMND-100 drug in Part A of its Phase I/II clinical trial for Alcohol Use Disorder, clearing the path for further clinical development.
Key Events · Product Development and Regulatory · CMND
-
CMND-100 Achieves Primary Safety Endpoint
The drug candidate for Alcohol Use Disorder (AUD) demonstrated a consistent safety and tolerability profile across all dose-escalation cohorts in Part A of its Phase I/II clinical trial.
-
No Serious Adverse Events Reported
All 24 participants completed treatment with no serious adverse events observed, reinforcing the drug's safety at doses up to 160 mg.
-
Advances to Next Clinical Stage
The positive safety findings enable Clearmind to progress to subsequent stages of the clinical program, including dosing AUD patients.
Analysis · CMND · Life Sciences
Clearmind Medicine announced that its CMND-100 drug candidate for Alcohol Use Disorder successfully met the primary safety and tolerability endpoint in Part A of its FDA-regulated Phase I/II clinical trial. All 24 participants completed treatment across ascending doses with no serious adverse events, demonstrating consistent tolerability. This positive outcome de-risks the early development stage and allows the company to advance to dosing AUD patients, which is critical for a small clinical-stage biotech.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.43 to $524.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.